Truvian’s Post

Providing the best care for people with diabetes means making sure that they feel welcome, supported, comfortable, and understood at every healthcare appointment they have. However, the physical environment and the equipment used throughout a healthcare visit can sometimes contribute to stigma. This checklist, designed for healthcare professionals, aims to help you create a stigma-free clinical environment. Click this link to visit our “Creating a Stigma-Free Clinic” checklist and learn more - https://bit.ly/4avB0Z1 This resource was created for dStigmatize, a diaTribe Foundation program, with support from Lilly, AstraZeneca, and the Boehringer Ingelheim-Lilly Alliance. #DiabetesStigma #Diabetes #T1D #T2D ⁠

Understanding IV Incompatibility: A Critical Component of Patient Safety In the healthcare field, ensuring patient safety is paramount. One crucial aspect often underemphasized is intravenous (IV) incompatibility. IV incompatibility occurs when medications or solutions react negatively with one another when combined in the same IV line, leading to reduced efficacy or potentially harmful effects. 🔍 Why is it important? Patient Safety: Incompatible mixtures can cause adverse reactions ranging from mild discomfort to severe health complications. Efficacy of Treatment:The therapeutic effect of medications can be compromised, leading to suboptimal treatment outcomes. Operational Efficiency: Preventing incompatibilities can reduce the occurrence of IV line blockages, saving time and resources. 💡 Key Considerations: -Knowledge and Training:Continuous education for healthcare professionals on the latest compatibility guidelines is essential. - Utilizing Technology: Leveraging electronic health records (EHR) and IV drug compatibility databases can aid in real-time decision-making. - Standard Protocols:Implementing standardized protocols for checking compatibility before administering IV medications. Let’s prioritize this critical aspect to enhance patient care quality. Have you experienced challenges with IV incompatibility in your practice? Share your insights and strategies below! #Healthcare #PatientSafety #IVIncompatibility #MedicalProfessionals #Pharmacy

Questions about prescribing LDN for your patients, and third-party testing of compounded medications? Listen to this important interview on the LDN Radio Show with Linda Elsegood, of LDN Research Trust, and Samantha Lebsock, PharmD. https://lnkd.in/epHEaTPc

World Pharmacists Day, observed on September 25, highlights the crucial role pharmacists play in healthcare systems globally. Pharmacists are essential in ensuring the safe and effective use of medications, providing expert guidance on drug therapies, and offering patients valuable health advice. They contribute significantly to public health by improving patient outcomes and ensuring the well-being of communities. Pharmacists work in various settings, from hospitals to local pharmacies, ensuring that patients receive the right medications and optimal care. Their efforts are vital to promoting health and preventing disease, making them indispensable members of the healthcare system. #worldpharmacistsday #healthcareheroes #pharmacistsinhealth #medicinesafety #pharmacistappreciation #evergreenclubapp #seniorstodaymagazine #seniorstoday

The FDA recently released a final rule and draft guidance concerning oversight of laboratory developed tests, a category of in-vitro diagnostic tests developed and performed within a single laboratory. To understand how these policies will impact laboratories, the diagnostics industry, patients, healthcare providers, and payers, reach out to an #AvalereExpert today: https://lnkd.in/eWHHXKNx #LDT #LDTs #laboratorydevelopedtests #diagnostics #diagnosticsindustry #healthcare #providers #patients #manufacturers #healthpolicy

Did you know that #pharmacists can play an important role in assessing symptoms and medications while making recommendations for a patient's functional status and goals of care? As access to #PalliativeCare expands in our region, the Avanti team looks forward to opportunities to collaborate and serve. #MedicationManagement https://lnkd.in/eMCKmPb4

...or maybe not that much. For one thing, there is a social desirability bias: given that the ICER has successfully positioned itself in the US as the arbiter of "scientific pricing", industry peeps are unlikely to answer that their reports are totally irrelevant - it would sound retrograde. And the other thing: it is possible to find interesting tidbits in an ICER report, while not actually using their calculations to drive (net) prices. I recall an earlier survey (and alas, not so precisely that I can provide a reference) that described exactly that: "useful backgrounder on the disease, patients' views, extant clinical data in the space, etc. - but not interested in their modeled prices". In the survey excerpts presented here, note the soft language: "identify concerns", "get a sense of" and the mushy "inform". Things only come into focus with the last question, pertaining to "changing formulary coverage". Pray tell! I look forward to the full survey. #drugpricing

New blog post: Tips for Coding OASIS N0415 High-Risk Drug Classes: Understanding the home health coding of the new OASIS N0415 High-Risk Drug Classes: Use and Indication item. https://lnkd.in/gyhFRtak #homehealthcare #homehealthprovider #homehealthnurse

Many clinical factors contribute to ASCVD, and many interventions exist to help lower the risk. Aside from encouraging patients to change their habits and behaviours (i.e. to stop smoking, eat healthier, incorporate more exercise in their lifestyle), pharmacological interventions mostly involve generic drugs with a low budget impact for healthcare systems. However, there remain patients who develop fatal or non-fatal myocardial infarction or strokes despite treatment, leading to a high burden on healthcare systems. Hence there remains a clinical need for interventions to successfully identify and treat these patients at very high risk to develop ASCVD events. After years of limited new product launches, there are currently a wealth of products in clinical trials, with new modes of action to tackle ASCVD-related conditions. New treatments give hope to physicians and patients alike, to be able to prevent this deadly condition. But, what about payers? •What will it take to gain approvals and funding, and even premium pricing in a world where drug expenditure continues to increase? •What evidence do payers need to see to make positive pricing and reimbursement decisions? •Will there be an appetite for innovative contracting and if so, what could it look like? •What will be impact be of the IRA in the US on price pressures? •Will the JCA in EU influence evidence needs in some markets? • If these questions resonate with you, our new ASCVD syndicated payer study can help you find the answers. Our study delivers a report that talks to your situation and gives you actionable recommendations. Contact me to find out more about our syndicated payer research into ASCVD in US, EU4 + UK (other markets possible on request) we can help you solve your problems. #IpsosHealthcare #payer #marketaccess #ASCVD

What are the biggest challenges facing NHS primary care in 2024–25? What impact will these have on relationships with industry? In this NHS Whispers webinar, we will be exploring the future of primary care, and the current and potential impact of recent policy announcements with a panel of NHS Associates. To join us live tomorrow at 2.00pm, register now at: https://lnkd.in/eKX_GcZw Learn more about this free webinar at: https://lnkd.in/eWNH_CMu #NHS #primarycare #NHSinsights #NHSWhispers #marketaccess #GPcontract #planning #Pharma #Medtech #MedicalDevices #Diagnostics